Royalty Pharma plcRPRXNASDAQ
Loading
EV to Sales HistoryNormalizing
Percentile Rank40
3Y CAGR+1.2%
5Y CAGR-1.6%
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
+1.2%/yr
vs -2.7%/yr prior
5Y CAGR
-1.6%/yr
Consistent
Acceleration
+3.9pp
Accelerating
Percentile
P40
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive growthNormalizing
PeriodValueYoY Change
202510.52+31.9%
20247.98+3.0%
20237.74-23.7%
202210.15+5.3%
20219.65-15.5%
202011.42-4.8%
201911.99+5.7%
201811.34-14.4%
201713.26-20.3%
201616.64-